Patents by Inventor Sheldon Penman

Sheldon Penman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6153729
    Abstract: Nuclear matrix targeting peptides (NMTPs) capable of delivering a variety of therapeutic and diagnostic agents, such as transcription regulatory factors, to the nuclear matrix of a cell are disclosed.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: November 28, 2000
    Assignees: St. Jude's Children's Research Hospital, University of Massachusetts
    Inventors: Gary S. Stein, Andre J. van Wijnen, Janet L. Stein, Jane B. Lian, Jeanne Lawrence, Cong-Mei Zeng, Lindsay Shopland, Scott Hiebert, Shari Meyers, Sheldon Penman
  • Patent number: 5273877
    Abstract: Disclosed are non-histological methods for determining the presence in a sample of a preselected cell type such as a malignant or genetically defective cell, or cell nucleus debris from such cells. The methods involve determination of an intranuclear matrix protein, the mRNA encoding that protein, or matrix protein associated DNA or RNA which acts as a marker for the preselected cell type, the presence of which indicates the presence of the cell type in the test sample. The intranuclear matrix marker protein or nucleotide are detected by hybridization, immunoassay, or other known means.
    Type: Grant
    Filed: June 30, 1988
    Date of Patent: December 28, 1993
    Assignee: Massachusetts Institute of Technology
    Inventors: Edward G. Fey, Sheldon Penman
  • Patent number: 4885236
    Abstract: A biochemical procedure for identification and characterization of cells in a biopsy or sample of a body fluid. The method can be used to determine cell type, i.e. epidermal, neuronal; tissue of origin, i.e. breast tissue, liver tissue; and degree of abnormality. The procedure can also be used to make antibodies and hybridization probes to detect cell or tissue specific antigens and nuclear matrix associated nucleic acids in cellular material and body fluids.The procedure is based on the isolation and analysis of the components of a specific subcellular protein fraction referred to here as the "nuclear matrix". The nuclear matrix includes proteins and nuclear matrix associated DNA specific to different cell types. These proteins and nucleic acids are altered or new ones expressed as a result of viral infection, genetic defects or malignancy.
    Type: Grant
    Filed: December 23, 1986
    Date of Patent: December 5, 1989
    Assignee: Massachusetts Institute of Technology
    Inventors: Sheldon Penman, Edward G. Fey
  • Patent number: 4882268
    Abstract: A biochemical procedure for diagnosis of three important properties of cells in a biopsy or blood sample: tumor type i.e., the tissue type that has become neoplastic; tissue of origin if the tumor has arisen from a metastasis; and degree of malignancy. The procedure can also be used to obtain antibodies which can be used to determine tissue of origin by immunostaining and to detect tumor antigens appearing in blood by radioimmunoassay.The procedure consists of isolating and analyzing components of a specific subcellular fraction referred to here as the "nuclear matrix". The nuclear matrix consists of proteins specific to different cell types and nuclear matrix associated DNA. The electrophoretic pattern of the proteins and restriction endonuclease digested DNA is unique and reproducible within a particular cell type and is therefore useful in diagnosing cell type. Changes in these patterns following transformation to a malignant phenotype provide additional diagnostic information.
    Type: Grant
    Filed: December 24, 1985
    Date of Patent: November 21, 1989
    Assignee: Massachusetts Institute of Technology
    Inventors: Sheldon Penman, Edward G. Fey
  • Patent number: 4569916
    Abstract: A composition is tested to determine whether it is a tumor promoter or a complete carcinogen by exposing a stable epithelial cell line to the composition for an incubation time period sufficient to induce morphological changes in the cell line. After the incubation time, the cells are observed by morphology changes induced by the composition, which changes are compared to that caused by a known tumor promoter or a known complete carcinogen.
    Type: Grant
    Filed: May 21, 1984
    Date of Patent: February 11, 1986
    Assignee: Massachusetts Institute of Technology
    Inventors: Sheldon Penman, Edward G. Fey
  • Patent number: RE35747
    Abstract: A biochemical procedure for identification and characterization of cells in a biopsy or sample of a body fluid. The method can be used to determine cell type, i.e. epidermal, neuronal; tissue of origin, i.e. breast tissue, liver tissue; and degree of abnormality. The procedure can also be used to make antibodies and hybridization probes to detect cell or tissue specific antigens and nuclear matrix associated nucleic acids in cellular material and body fluids.The procedure is based on the isolation and analysis of the components of a specific subcellular protein fraction referred to here as the "nuclear matrix". The nuclear matrix includes proteins and nuclear matrix associated DNA specific to different cell types. These proteins and nucleic acids are altered or new ones expressed as a result of viral infection, genetic defects or malignancy.
    Type: Grant
    Filed: November 19, 1991
    Date of Patent: March 17, 1998
    Assignee: Massachusetts Institute of Technology
    Inventors: Sheldon Penman, Edward G. Fey